Sumitomo Pharma America receives USFDA approval of vibegron for benign prostatic hyperplasia
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
GEMTESA is the first and only beta-3 agonist approved for the treatment of men with OAB symptoms who are receiving pharmacological therapy for BPH
This approval is a significant achievement in expanding the availability of this critical therapeutic,
This facility is considered to be in a minimally acceptable state of compliance with regard to current GMP
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Subscribe To Our Newsletter & Stay Updated